Table 4 Baseline characteristics and treatment outcome measures according to ARMS2 rs10490924 genotypes
| Â | Â | Genotype | OR (95% CI)* | P - value | ||
|---|---|---|---|---|---|---|
| Â | Â | TT (34) | TG (35) | GG (11) | ||
Baseline characteristics | Age | 67.0 ± 8.7 | 68.4 ± 8.1 | 66.7 ± 7.2 | – | 0.556** |
Sex (male/female) | 20 (58.8%)/14 | 20 (57.1%) / 15 | 8 (72.7%) / 3 | – | 0.508†| |
Smoking (ever/never) | 12 (35.3%)/20 | 15 (42.9%) / 20 | 5 (45.5%) / 6 | – | 0.933†| |
Baseline BCVA, letter | 53.1 ± 22.0 | 45.6 ± 20.8 | 56.8 ± 12.6 | – | 0.076** | |
Baseline TFT, μm | 427.1 ± 222.1 | 452.6 ± 195.6 | 325.8 ± 102.8 | – | 0.188** | |
Baseline PED height | 307.3 ± 127.4 | 299.1 ± 142.2 | 241.0 ± 132.1 |  | 0.203** | |
Baseline vascular lesion area, mm2 | 6.9 ± 5.4 | 5.5 ± 4.3 | 3.2 ± 2.9 | – | 0.067** | |
Treatment outcome measures (at month 12) | BCVA change from baseline, letter | +0.9 ± 17.7 | +9.1 ± 19.5 | +5.4 ± 14.3 | – | 0.338††|
|  | TFT change from baseline, μm | −36.8 ± 270.7 | −113.3 ± 226.7 | −110.1 ± 100.0 | – | 0.212††|
≥ 15 letter gain | 8 (23.5%) | 13 (37.1%) | 4 (36.4%) | 1.58 (0.78–3.23) | 0.208††| |
Dry status on OCT | 14 (41.2%) | 15 (42.9%) | 5 (45.5%) | 1.19 (0.56–2.53) | 0.622††| |
PED regression on OCT | 9 (26.4%) | 16 (45.7%) | 7 (63.6%) | 2.96 (1.38–6.36) | 0.004††| |
Polyp regression on ICGA | 8 (32.0%)/25 | 8 (34.8%)/23 | 3 (42.9%)/7 | 1.27 (0.85–1.90) | 0.215††| |
Number of injection | 5.7 ± 2.1 | 5.6 ± 1.7 | 5.7 ± 1.8 | – | 0.786††| |